Qatar Free Zones Authority (QFZ) and Russia’s BIOCAD, a leading biotechnology company, have signed a Memorandum of Understanding (MoU) to establish biotechnology and pharmaceuticals activities in Qatar’s Free Zones.
The MoU was signed by HE Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani, CEO of Qatar Free Zones Authority (QFZ) and Dmitrii Sivokoz, CEO of BIOCAD. The signing ceremony, took place during Qatar – Russia Business Forum, was also attended by high-ranking officials from both countries, alongside distinguished industry leaders and guests.
The signing of MoU was also witnessed by Maxim Reshetnikov, Minister of Economic Development of the Russian Federation Maxim Reshetnikov, along with Qatar Minister of Commerce and Industry.
The MoU seeks to foster cooperation across areas such as new technologies, logistics and biomedical sciences. BIOCAD also plans to encourage its partners and suppliers to set up operations in Qatar’s Free Zones as part of expanding Qatar’s biomedical sciences ecosystem.
Additiobally, BIOCAD plans to support local research and development and engage with top universities and research institutions in Qatar, fostering academic-industry partnerships and involving the local scientific community in collaborative R&D initiatives.
HE Sheikh Mohammed bin Hamad bin Faisal Al-Thani CEO – QFZ
“Our partnership with BIOCAD is a strategic step in positioning Qatar as a hub for biomedical innovation. It reflects QFZ’s commitment to attracting future-focused industries and advancing the goals of the Third National Development Strategy and Qatar National Vision 2030.”
Recently, a delegation from the Qatari Ministry of Public Health and the Russian Federation have engaged in discussions with an emphasis on BIOCAD’s R&D and manufacturing facilities.
During the meeting, the parties centered on potential cooperation in providing Qatar’s population with modern, effective, and safe medications, such as pharmaceutical localization and the establishment of biotechnological production within Qatar.
Dmitry Sivokoz added that, “The company is interested in entering the Qatari pharmaceutical market not just as a supplier of its products, but also as a reliable state partner, contributing to the development of the country’s own pharmaceutical industry through the transfer of technology for the production of biotechnological medicine for Qatar and global markets. This cooperation would not only improve access to high-efficacy therapies for Qatari patients but also foster the development of the local pharmaceutical industry and strengthen bilateral ties between Russia and Qatar.”
Aligning with Qatar’s mission to emerge as a globally recognized center for biomedical sciences innovation and high-tech research and development, this partnership highlights the country’s commitment to enabling advanced industries that serve both the national interest and global health outcomes.
